Dr. Dorritie on Determining Transplant Eligibility in Multiple Myeloma
In Partnership With:
Kathleen A. Dorritie, MD, discusses transplant eligibility in multiple myeloma.
Kathleen A. Dorritie, MD, hematologist/medical oncologist, University of Pittsburgh Medical Center (UPMC) Hillman Cancer Center, discusses transplant eligibility in multiple myeloma.
Transplant eligibility criteria are continually evolving and vary based on geographic location. For example, in Europe, age may have a more significant role in determining whether a patient is eligible for transplant, Dorritie says.
Further, it’s important to be aware of the patient's comorbidities because transplants are known to be quite toxic. As such, patients who have an extensive history of cardiac or renal disease are not eligible for transplant, Dorritie adds.
Notably, trials such as the phase 3 MAIA trial, which evaluated the combination of daratumumab (Darzalex), lenalidomide (Revlimid), and dexamethasone vs lenalidomide/dexamethasone alone in patients with transplant-ineligible multiple myeloma, will help to determine whether transplant should be included in the treatment paradigm for patients with newly diagnosed multiple myeloma, Dorritie concludes.
